BTBP has continuously received a Wind ESG A rating, with a comprehensive score of 7.02

According to Tongbi Finance, on June 2, 2026, Beijing Tiantan Biological Products Co., Ltd. (stock abbreviation: Tiantan Biological, code: 600161.SH) received a Wind ESG rating of A, unchanged from the previous period. The company's comprehensive score is 7.02, higher than the biotechnology III industry average of 6.35. It ranks 52nd among 154 companies in the biotechnology III industry, placing it in the top 33.77% of the industry. The scores for environmental, social, and governance dimensions are 7.05, 5.30, and 6.05, respectively.

Compared to the previous rating, the comprehensive score decreased from 7.17 to 7.02, a decline of 0.15 points. The contribution from management practices dropped from 4.19 to 4.02, a decrease of 0.17 points. The contribution from controversy events remained stable at 3.00. In terms of dimensions, the environmental dimension improved by 0.14 points, while the social dimension decreased by 0.34 points, and the governance dimension fell by 0.18 points.

Rating Observation

In the environmental dimension, the company demonstrated multi-level practical capabilities from energy management systems to carbon verification certification. The company and its subsidiaries strictly implement internal systems such as the "Energy Management Manual" and "Energy Data Management System," with one subsidiary having obtained ISO 50001 energy management system certification. The total energy consumption is 26,837.85 tons of standard coal, with renewable energy accounting for 5.13%. In terms of clean energy utilization, the company has built a distributed photovoltaic project on the factory roof, generating 3.6 million kilowatt-hours annually, reducing carbon dioxide emissions by 386.28 tons per year, and plans to further increase the proportion of solar energy consumption. Additionally, the company completed ISO 14064 carbon verification and ISO 14067 product carbon footprint assessment, obtaining relevant certification. Although the practices in energy conservation and emission reduction are comprehensive, there is still room for improvement in information disclosure in the waste management area, particularly regarding the total amount and proportion of recycling.

In the social dimension, the company focuses on product quality management and R&D innovation, establishing a relatively complete management system. The company's subsidiary Chengdu Rongsheng has passed ISO 9001 quality system certification, its quality inspection department laboratory has obtained CNAS national accreditation, and several plasma testing laboratories have passed biosafety CNAS certification, forming a quality management system covering the entire process. In terms of R&D, the company's R&D investment reached 350.3614 million yuan, accounting for 5.68% of operating revenue, with R&D personnel making up 9.47% of the total workforce, and the total number of effective patents is 96. The company has also established the "Intellectual Property Management Measures" to strengthen intellectual property protection. Furthermore, the company has set up a drug vigilance management system and is promoting the "Three-Year Action Plan for Smart Supervision of Blood Product Production (2024-2026)" to enhance the informatization level of quality management. However, disclosures in areas such as supply chain certification and employee satisfaction are still insufficient, failing to fully demonstrate its social responsibility practices.

In the governance dimension, the company shows a certain level of standardization in board independence and anti-corruption management. The proportion of independent directors on the board is 37.5%, with the same proportion of female directors, and the attendance rate of board members reaches 100% The company has established four specialized committees: Strategy and Investment, Audit and Risk Management, Performance Assessment and Compensation, and Nomination Committee, forming a governance structure with clear responsibilities. In terms of anti-corruption, the company has strengthened management execution by signing the "Integrity Commitment Letter" and the "Anti-Commercial Bribery Commitment Letter," incorporating relevant requirements into contract terms. However, the current situation where the CEO also serves as the Chairman and the overlap of Compensation Committee members with executives may pose certain challenges to governance independence. Additionally, the mechanism linking ESG performance to executive compensation has not been disclosed, which warrants further attention.

Content generated by AI on June 2, 2026, please verify important information